RESEARCH MONOGRAPH · KDC-MN-207

Venlafaxine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

78/100

Effective SNRI with a discontinuation syndrome that should be its primary warning label

Venlafaxine is the original SNRI and arguably the drug that established that class as commercially viable, but it's also the drug whose discontinuation profile is bad enough that it deserves more honest discussion than it usually gets. Wyeth (now Pfizer) brought it to market in 1993, and the dose-dependent pharmacology is genuinely interesting because it changes character as you go up.

At low doses (around 75 mg/day) venlafaxine is functionally an SSRI: SERT inhibition dominates and NET inhibition is minimal. Above 150 mg/day NET inhibition becomes pharmacologically meaningful, and above 225 mg/day you start to see some dopamine reuptake effects. This dose-dependent receptor occupancy story is well-documented and it's part of why venlafaxine is often dosed higher than starting doses suggest. Half-life of the parent compound is 5 hours, the active metabolite O-desmethylvenlafaxine (desvenlafaxine, see KDC-MN-208) is 10-12 hours, and CYP2D6 polymorphism creates meaningful inter-individual variability.

The efficacy data is solid: venlafaxine has consistently performed at or near the top of meta-analyses for MDD response and remission rates, the GAD evidence is strong, and the broader anxiety-spectrum indications hold up. The Cipriani rankings have placed it near the top for efficacy in multiple analyses, though acceptability is lower because of the discontinuation issue.

What we don't like is the discontinuation syndrome, and we don't soften it. The 5-hour parent half-life plus aggressive serotonergic and noradrenergic downregulation produces a withdrawal pattern that's among the worst in the antidepressant pharmacopoeia. Brain zaps, dizziness, sweating, GI distress, irritability, sometimes lasting weeks. Hyperbolic tapering using liquid formulation or compounded reduction schedules is often necessary. The XR formulation helps a little but doesnt solve it.

Cardiovascular effects matter at higher doses: dose-dependent blood pressure elevation and tachycardia from the NET component. This is a real consideration for chronic dosing and is often underemphasized in the marketing-derived narrative.

Sourcing for research material is trivial, off-patent for years, USP / EP standards everywhere. For research it's a useful tool compound for studying dose-dependent NET / SERT pharmacology in the same molecule, which is rare. Clinically we'd consider duloxetine or levomilnacipran first for most SNRI indications because the discontinuation profiles are better.

Evidence: 92
Mechanism: 85
Reliability: 80
Safety: 65
Sourcing: 90
Value: 80
Signal: 70
Staying power: 65

Plain-language summary Intrigue 64 / 100

Venlafaxine (Effexor) was the first dual-action antidepressant, hitting both the serotonin and norepinephrine pumps in the same molecule. Wyeth got it approved in 1993. The catch is that the dual action depends on dose: at low doses it acts mostly like an SSRI; the norepinephrine effect only kicks in meaningfully above roughly 150 mg. The active leftover after the liver works on it does most of the heavy lifting at steady state, and that leftover is itself sold separately as desvenlafaxine. It has a notoriously brutal discontinuation profile because its half-life is short and patients feel every missed dose. Approved for depression, generalized anxiety, social anxiety, and panic disorder. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Serotonin-norepinephrine reuptake inhibitor

A bicyclic SNRI with dose-dependent transporter selectivity; the prototype dual-action antidepressant.

Abstract

Venlafaxine ((R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CAS 93413-69-5; molecular formula C17H27NO2; molecular weight 277.40) is a bicyclic phenethylamine SNRI developed at Wyeth and approved by the FDA in 1993 under the trade name Effexor. The compound is the prototype clinical SNRI, exhibiting dose-dependent transporter selectivity: at doses below 150 mg daily it functions as an SSRI (SERT inhibition predominates with NET inhibition becoming clinically meaningful only at higher doses); at 150 to 375 mg daily, NET engagement adds a noradrenergic component. The active metabolite O-desmethylvenlafaxine (desvenlafaxine, marketed separately as Pristiq) carries comparable transporter activity and contributes substantially to the steady-state effect. Plasma half-life of the parent compound is approximately 5 hours; the metabolite half-life is approximately 11 hours. Metabolism is via CYP2D6 (primary) and CYP3A4 (secondary). The compound exhibits a pronounced discontinuation syndrome, attributed to the short half-life and combined serotonergic-noradrenergic withdrawal. Used as the reference SNRI in mechanism studies and as a positive control in dual-action antidepressant pharmacology research.

Mechanism of action

Dose-dependent dual SERT/NET inhibition; SSRI-like at low doses, true SNRI at higher doses. Active metabolite O-desmethylvenlafaxine drives steady-state effect.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential. Drugs 1995.
Bymaster FP, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters. Neuropsychopharmacology 2001.
Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress Anxiety 2000.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-207

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Venlafaxine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs